Read today’s Kaiser Health News
In other news:
About hospitals and healthcare systems
Vizient announces 2025 Top Performers in clinical quality and sustainability excellence FYI
About pharma
Roche to pay $2.4B to acquire 89bio and its MASH hopeful pegozafermin: Roche agreed to acquire 89bio for $14.50 per share in cash, or around $2.4 billion, adding the late-stage FGF21 analogue pegozafermin to its cardiovascular, renal and metabolic disease portfolio. The deal announced Thursday also includes a contingent value right (CVR) worth up to $6 per share in cash, giving the transaction a total potential value of $3.5 billion. Eli Lilly pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial: KEY POINTS
Eli Lilly said its experimental pill outperformed Novo Nordisk’s own oral drug in the first head-to-head study comparing the two medicines in patients with Type 2 diabetes.
Eli Lilly said its pill, orforglipron, was superior at the trial’s main goal of lowering blood sugar levels at 52 weeks compared to Novo Nordisk’s oral semaglutide, and helped patients lose more weight.
But it’s less clear how Eli Lilly’s pill compares to a higher dose of oral semaglutide, especially in patients who are overweight or have obesity without diabetes.
Novo Nordisk shares pop 5% after Wegovy pill trial shows ‘significant’ weight reduction: Results from the phase 3 Oasis 4 trial showed the oral semaglutide pill led to average weight reduction of 16.6% after 64 weeks in patients with obesity or overweight and at least one weight-related comorbidity, the Danish pharmaceutical firm said.
About healthcare IT
“15% of Searches Have Never Been Typed Before”Why AI Safety in Health-Related Search Is Hard: …it turns out that 15% of what gets typed into the search box every day has never been typed in before. It's the first time that it's ever been typed in. That makes it a really interesting space to think about with the intersection of things that. by definition can't be in your training data because people are saying them literally for the first time in human history.
New AI model predicts susceptibility to over 1,000 diseases: The generative AI system called Delphi-2M was built at the European Molecular Biology Laboratory in Cambridge, using “similar architecture to large language models but with key innovations to work with healthcare data”, said Tom Fitzgerald of EMBL. Delphi was trained on anonymised medical records from 400,000 participants in UK Biobank. The researchers then tested the model successfully on data from 1.9mn patients in the Danish National Patient Registry. The predictions across more than 1,000 diseases generally matched the accuracy of existing tools that have a far narrower focus, such as the QRisk score for heart conditions. Results were published in Nature on Wednesday.